(Q46743851)

24 December 2017

title

Comparison of neuropsychiatric side effects in an observational cohort of efavirenz- and protease inhibitor-treated patients (English)

1 reference

24 December 2017

0 references

1 reference

Trevor Hawkins

1

1 reference

24 December 2017

Cindy Geist

2

1 reference

24 December 2017

Ben Young

3

1 reference

24 December 2017

A Giblin

4

1 reference

24 December 2017

Renee C Mercier

5

1 reference

24 December 2017

Karla Thornton

6

1 reference

24 December 2017

Richard Haubrich

7

1 reference

24 December 2017

language of work or name

1 reference

1 July 2005

1 reference

24 December 2017

published in

HIV Clinical Trials

1 reference

24 December 2017

volume

6

1 reference

24 December 2017

issue

4

1 reference

24 December 2017

page(s)

187-196

1 reference

24 December 2017

Management of sudden psychiatric disorders related to efavirenz

cites work

1 reference

https://api.crossref.org/works/10.1310%2F92VR-FP24-J8GA-B49Q

Long-term assessment of neuropsychiatric adverse reactions associated with efavirenz

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2F92VR-FP24-J8GA-B49Q

Central nervous system adverse effects with efavirenz: case report and review

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2F92VR-FP24-J8GA-B49Q

Effects of depressive symptoms and mental health quality of life on use of highly active antiretroviral therapy among HIV-seropositive women

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2F92VR-FP24-J8GA-B49Q

The Impact of Apathy and Depression on Quality of Life in Patients Infected with HIV

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2F92VR-FP24-J8GA-B49Q

Substance use and mental health correlates of nonadherence to antiretroviral medications in a sample of patients with human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2F92VR-FP24-J8GA-B49Q

Underdiagnosis of depression in HIV: who are we missing?

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2F92VR-FP24-J8GA-B49Q

Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and long-lasting viral suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2F92VR-FP24-J8GA-B49Q

Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2F92VR-FP24-J8GA-B49Q

Preliminary Data of a Prospective Study on Neuropsychiatric Side Effects After Initiation of Efavirenz

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2F92VR-FP24-J8GA-B49Q

10.1310/92VR-FP24-J8GA-B49Q

21 January 2018

Identifiers

DOI

1 reference

24 December 2017

1 reference

24 December 2017